Employees (Fewer Than 10 Rate)

Statutory and Regulatory Analysis of the “Fewer Than 10” Rate in the New York Life Sciences Research and Development Tax Credit Program

The “Employees (Fewer Than 10 Rate)” in the New York Life Sciences Research and Development Tax Credit refers to a preferential 20% credit rate applied to the qualified research expenditures of certified new businesses that maintain a workforce of nine or fewer full-time employees on the final day of the taxable year. This heightened rate, compared to the standard 15% for larger firms, serves as a targeted financial catalyst designed to provide maximum liquidity to early-stage startups during their most capital-intensive phases of discovery and development.

The implementation of this tiered credit system is a central component of New York’s broader economic strategy to position the state as a global leader in the life sciences sector. By providing a 20% refundable credit for companies with fewer than 10 employees, the state acknowledges the unique challenges faced by nascent biotech and pharmaceutical ventures, which often lack the revenue streams necessary to benefit from traditional non-refundable tax incentives. This program is administered through a collaboration between Empire State Development (ESD), which oversees certification and allocation, and the New York State Department of Taxation and Finance, which manages the processing of claims and the issuance of refunds. Unlike many federal incentives that require an incremental increase in research spending over a historical base, the New York Life Sciences credit utilizes a fixed-rate method, applying the percentage directly to the total qualified research expenditures (QREs) incurred within the state’s borders. This structure is particularly advantageous for new businesses that do not have a multi-year financial history, allowing them to capture significant value from their very first dollar of research investment.

The Statutory Framework of New York Tax Law Section 43

The legal foundation for the Life Sciences Research and Development Tax Credit is codified under New York Tax Law Section 43. This statute establishes the eligibility criteria, the credit calculation methodology, and the administrative oversight required to maintain the program’s integrity. Under Section 43(a), a taxpayer that is a qualified life sciences company, or a member of a partnership or S-corporation that is a qualified life sciences company, is entitled to a credit against the taxes imposed by Article 9-A (the corporate franchise tax) or Article 22 (the personal income tax).

The law explicitly defines the tiered rate structure in Section 43(b). It mandates that for a company employing ten or more persons during the taxable year, the credit shall be 15% of the research and development expenditures in the state. However, for those entities that employ fewer than ten persons, the rate is increased to 20%. This legislative distinction is intended to skew the benefits toward smaller, more agile research teams that are often in the “seed” or “Series A” stages of funding. The statute also imposes a strict limit on the duration of the benefit, allowing the credit only for the first taxable year in which the criteria are met and for the two subsequent taxable years, provided the company remains eligible.

The total amount of credit allowed to any single company, or to a combined group of companies, is capped at $500,000 per year. This annual cap ensures that the state’s total allocation—which is limited to an aggregate of $10 million per year across all participants—is not exhausted by a handful of large-scale enterprises. This $10 million pool is allotted from funds available under Article 17 of the Economic Development Law, and the Department of Economic Development is directed to allocate these credits based on the priority of the application filing date.

Feature of Section 43	Regulatory Detail	Statutory Reference
Primary Credit Rate	20% for fewer than 10 employees	NY Tax Law § 43(b)(2)(i)
Secondary Credit Rate	15% for 10 or more employees	NY Tax Law § 43(b)(2)(i)
Annual Credit Cap	$500,000 per entity or group	NY Tax Law § 43(b)(3)
Duration of Eligibility	3 consecutive taxable years	NY Tax Law § 43(b)(2)(ii)
Aggregate State Cap	$10 million annually	NY Tax Law § 43(b)(4)
Refundability	Fully refundable if liability is zero	NY Tax Law § 43(f)

Determining the Headcount: The “Snapshot Rule” and Officer Exclusions

The determination of whether a company “employs fewer than 10 persons” is not a subjective assessment or a rolling average of employment throughout the year. Instead, the New York State Department of Taxation and Finance and Empire State Development adhere to a specific regulatory mechanism known as the “snapshot rule.” According to Section 43(g), the number of employees is determined by counting the individuals employed full-time by the company on the thirty-first day of December of the taxable year. For entities that operate on a fiscal year that does not coincide with the calendar year, the count is taken on the final day of their respective taxable period.

This snapshot approach provides a high degree of certainty for tax planning but also requires precise timing. For instance, a company that has nine employees for most of the year but hires a tenth person on December 30th would see its credit rate drop from 20% to 15% for the entire year’s expenditures. Conversely, a company that experiences attrition and drops below the ten-person threshold just before the end of the year could potentially qualify for the higher 20% rate.

The Exclusion of General Executive Officers

A critical nuance in the headcount calculation is the mandatory exclusion of “general executive officers”. Under the statutory guidelines, these individuals are not counted toward the ten-person threshold. The definition of a general executive officer is drawn from the broader corporate franchise tax regulations under Article 9-A. Generally, this category includes:

• The Chairperson of the Board
• The President and Vice-Presidents
• The Secretary and Assistant Secretaries
• The Treasurer and Assistant Treasurers
• The Comptroller

For an individual to be classified as a general executive officer, they must be appointed or elected in accordance with the company’s bylaws and must perform general executive duties that affect the management and control of the corporation as a whole. In the context of a life sciences startup, this exclusion is particularly beneficial. Many early-stage firms are led by a small group of founders who serve as officers. If a startup has twelve total employees, but four of them are officers (e.g., CEO, CSO, COO, and CFO), the “effective” headcount for the tax credit would be eight. This allows the company to remain eligible for the 20% rate even as it expands its technical and laboratory staff.

Definition of Full-Time Employment

The statute specifies that only “full-time” employees are included in the headcount. While New York law across various programs occasionally uses different metrics for full-time status, the general guidance for the Life Sciences R&D credit aligns with the requirement for individuals to work at least 30 to 35 hours per week on a consistent basis. Part-time employees, independent contractors, and 1099 consultants are generally excluded from the headcount for the purpose of the 15% vs. 20% rate determination, although the wages of part-time employees may still be eligible for inclusion in the qualified research expenditure (QRE) base if they are directly involved in research activities.

Qualified Life Sciences Company Certification

To access the “Fewer than 10” rate, a business must first receive certification from Empire State Development as a “qualified life sciences company”. This is a two-pronged test requiring the entity to prove both its scientific focus and its status as a new business.

Scientific Scope and “Majority of Efforts” Test

A qualified life sciences company is defined as a business entity or organization that devotes the majority of its efforts to the various stages of research, development, technology transfer, and commercialization related to any life sciences field. The state provides a broad but exhaustive list of qualifying fields:

• Biopharmaceuticals and Biogenerics: Focused on the discovery and synthesis of therapeutic agents.
• Medical Diagnostics and Devices: Engineering and testing of tools for clinical use.
• Genomics and Bioinformatics: Analyzing genetic data and biological information through computational means.
• Agricultural Biotechnology: Research into plant and animal health and production.
• Regenerative Medicine and Stem Cell Research: Development of therapies to repair or replace damaged tissue.
• Medical Nanotechnology and Health Robotics: Advanced engineering at the intersection of biology and machinery.

The “majority of efforts” requirement is verified by ESD through an analysis of the company’s business plan, its allocation of human resources, and its capital expenditures. If a company is a conglomerate with only a minor division focused on life sciences, it may fail this threshold unless the life sciences component is legally segregated into a separate entity that meets the criteria.

The “New Business” Eligibility Hurdle

The Life Sciences R&D Tax Credit is strictly reserved for “new businesses”. This requirement is intended to prevent established corporations from spinning off existing departments into “new” entities simply to harvest the credit. Under NY Tax Law Section 43(c)(2), a business must meet the definition of a new business found in Section 210-B(1)(f) or Section 606(a)(10).

The criteria for a new business are rigorous:

• The business must not be operating or located within the state at the time it submits its application (for entities relocating to NY) or must be newly formed.
• The business must not be “substantially similar” in operation and ownership to another business entity that is or was previously taxable in New York.
• The entity must not have been a “related person” to another New York taxpayer within the immediately preceding sixty months.
• The business must not be the result of a merger, acquisition, or reorganization of an existing firm that has already operated in the state.

For many venture-backed startups, the “related person” rule can be complex. If a venture capital firm owns a significant stake in multiple New York life sciences companies, ESD will scrutinize the relationships to ensure each startup is a truly independent venture. ESD is mandated to verify these conditions before issuing a Certificate of Tax Credit.

Qualified Research Expenditures (QREs) in the New York Context

The 20% rate is applied to a specific pool of expenses known as Qualified Research Expenditures (QREs). While New York references Internal Revenue Code (IRC) Section 41(b) for the general definition of these expenses, the state has instituted specific modifications that taxpayers must navigate.

Eligible Categories of Expenditure

The credit base in New York consists of three primary categories of expense, provided they are incurred within the state on or after January 1, 2018:

1. In-House Research Wages: This includes the salaries and wages paid to employees for performing “qualified services”. Qualified services include the actual conduct of research, the direct supervision of research, or the direct support of research activities. For companies at the 20% rate, the wage component is typically the largest driver of the credit.
2. Supplies: This covers the cost of tangible property used in the conduct of research. This includes laboratory chemicals, reagents, disposable equipment, and other materials consumed during experiments. Notably, this does not include capitalized assets like heavy machinery or buildings, which are subject to different tax treatments.
3. Computer Use Costs: New York allows the inclusion of costs associated with the right to use computers for research purposes. This is an increasingly important category for genomics and bioinformatics firms that utilize high-performance cloud computing platforms (such as AWS, Google Cloud, or Microsoft Azure) to process vast amounts of biological data.

The Contract Research Exclusion

The most significant regulatory divergence from the federal R&D tax credit is New York’s treatment of contract research. Under the federal IRC Section 41, taxpayers can typically include 65% of the fees paid to third-party contractors for research services. New York State explicitly excludes these expenses for the Life Sciences R&D Tax Credit.

The rationale for this exclusion is to ensure that the tax subsidy directly supports the development of a local workforce and the maintenance of intellectual property within the New York-based entity. For a small startup with fewer than 10 employees, this requires a strategic decision: while outsourcing research to a Contract Research Organization (CRO) may be operationally efficient, those costs will not generate a 20% credit. To maximize the credit, the startup must perform the work in-house using its own employees and supplies.

Geographic Sourcing and Nexus

To qualify for the New York credit, the expenses must be incurred “in this state”. For wages, this is generally determined by whether the employee is performing their services at a New York location. For supplies, the rule focuses on where the materials are used. For computer costs, the “right to use” must be connected to the research conducted within the state. This geographical nexus is strictly enforced; a company with a laboratory in Manhattan and a data processing center in New Jersey must bifurcate its expenses and only claim those attributable to the Manhattan facility.

Expenditure Type	Federal Treatment (IRC 41)	NY Life Sciences Treatment
Wages for Research	Fully Qualified	Fully Qualified (NYS only)
Laboratory Supplies	Fully Qualified	Fully Qualified (NYS only)
Cloud Computing/Rentals	Qualified	Fully Qualified (NYS only)
Contract Research	65% Qualified	Excluded
Calculation Method	Incremental over Base Period	Fixed-Rate on Total QREs

Administrative and Procedural Guidance from State Revenue Offices

The Life Sciences R&D Tax Credit is not an “automatic” credit that a taxpayer simply calculates on their return. It requires a rigorous multi-step administrative process involving Empire State Development (ESD) and the Department of Taxation and Finance.

The Application for Certification

The process begins with the submission of a Consolidated Funding Application (CFA) through the ESD portal. This application must be filed annually for each year the company wishes to claim the credit. Applicants are required to provide detailed information regarding their research activities, their headcount (to justify the 20% or 15% rate), and their anticipated qualifying expenditures.

ESD reviews these applications on a first-come, first-served basis. This makes the timing of the application critical. Because there is a $10 million statewide cap, an application filed early in the year has a much higher probability of securing an allocation than one filed after the cap has been reached. If the cap is exhausted, subsequent applications are rolled over to the following year’s allocation, which can significantly delay the receipt of the refund.

The Certificate of Tax Credit

Upon successful review, ESD issues a Certificate of Tax Credit. This document is the legal evidence required to claim the credit on a tax return. The certificate includes the specific amount of credit authorized for the tax year and a unique certificate number. It also explicitly states the tax year in which the credit must be claimed. Taxpayers must file their claim in the specific year indicated on the certificate; they cannot unilaterally choose to defer or accelerate the credit.

Filing the Claim with the Tax Department

Once the taxpayer has received their certificate, they must file the appropriate forms with the New York State Department of Taxation and Finance.

• For Corporations (C-Corps and S-Corps): The claim is made on Form CT-648, Life Sciences Research and Development Tax Credit. This form must be attached to the corporate franchise tax return (Form CT-3 or CT-3-S). The corporation must enter the credit amount exactly as it appears on the ESD certificate, up to the $500,000 limit.
• For Pass-Through Entities and Individuals: The claim is made on Form IT-648, Life Sciences Research and Development Tax Credit. This applies to sole proprietors, partners in partnerships, and shareholders of S-corporations. The form collects the certificate information and calculates the share of the credit attributable to each individual taxpayer.

A copy of the actual ESD Certificate of Tax Credit must be submitted with the tax return. Failure to attach the certificate is one of the most common reasons for a summary denial of the credit.

The Refund Mechanism

If the credit amount exceeds the taxpayer’s tax liability for the year, the difference is treated as an overpayment of tax. The taxpayer can elect to have this overpayment refunded in cash or applied to the following year’s estimated tax. For most startups with “fewer than 10 employees,” the tax liability is minimal (often only the fixed dollar minimum tax), meaning the vast majority of the credit is issued as a cash refund. It is important to note that the state does not pay interest on these refunds or overpayments.

Scenario Analysis: The Practical Application of the 20% Rate

To better understand the interaction between headcount, officer exclusions, and expenditure calculations, consider the following detailed scenario involving an emerging medical device company.

Case Study: BioVascular Systems, LLC

The Profile:

BioVascular Systems is a newly formed LLC in Rochester, New York, developing a novel nanotechnology-based stent. The company has been certified as a qualified life sciences company by ESD and is in its second year of operation.

The Workforce (as of December 31st):

• Officers: 2 (Managing Member/CEO and Chief Financial Officer).
• Technical Staff: 7 Full-time lab researchers.
• Administrative Staff: 1 Part-time assistant (20 hours/week).
• Total Headcount: 10 People.

The Financials:

• Wages for NY-based Lab Research: $1,800,000.
• Lab Supplies Purchased in NY: $400,000.
• Contract Research (Clinical Trials in Buffalo): $500,000.
• Cloud Computing Costs (Data Modeling): $100,000.

Step 1: Headcount and Rate Determination

BioVascular must determine if it qualifies for the 20% “Fewer than 10” rate or the 15% rate.

• The total headcount is 10.
• The 2 general executive officers are excluded from the count.
• The part-time assistant is excluded because the statute specifies “full-time” employees.
• Adjusted Headcount: 7 Employees.
• Applicable Rate: 20%.

Step 2: Calculation of Qualified Research Expenditures (QREs)

BioVascular must identify which expenses are eligible for the credit base.

• Research Wages: $1,800,000 (Included)
• Supplies: $400,000 (Included)
• Cloud Computing: $100,000 (Included)
• Contract Research: $500,000 (Excluded per NYS rules).
• Total NY QREs: $2,300,000.

Step 3: Final Credit and Refund Amount

• Calculated Credit: $2,300,000 x 20% = $460,000.
• Because $460,000 is below the $500,000 annual cap, the full amount is authorized by ESD.
• BioVascular files its tax return. It has a minimum tax liability of $25.
• Refund Check Received: $459,975.

Analysis of the Outcome

In this scenario, BioVascular preserved its 20% rate by properly identifying its officers and the status of its part-time staff. Had the company miscalculated and fallen into the 15% bracket, its credit would have dropped to $345,000—a loss of $115,000 in immediate cash flow. Furthermore, the company’s decision to spend $500,000 on contract research, while perhaps necessary for the clinical trials, did not yield any tax benefit at the state level. If BioVascular could have performed that research in-house by hiring more staff (while staying under the 10-person officer-adjusted limit), it could have captured an additional $100,000 in credit value.

Economic Impact and Program Performance Statistics

The “Fewer than 10” rate is not merely a theoretical benefit; it has driven significant activity in the New York life sciences ecosystem since the program’s inception. Data from the Life Science Initiative’s 2023 and 2024 annual reports highlight the program’s reach.

Statewide Utilization and Growth

As of October 2023, the state reported that $18.2 million in R&D and Excelsior Job Program tax credits had been funded since the start of the Life Science Initiative. During the period from April 2022 to October 2023 alone, $3.66 million in Life Science R&D tax credits were issued against total qualified expenses of $34.68 million. This represents a significant leverage of private investment by the state.

The 2024 Annual Report notes that the Life Science Initiative has a total budget of $620 million, which includes $200 million dedicated specifically to tax credits for R&D and job creation. The impact on the state’s economy is evident in the following figures:

Key Economic Indicator	Growth/Impact (2017-2022)
Life Science Job Growth Rate	18.5% increase in NYS
New Companies Formed/Retained	32 companies via ESD funding
New Patents Filed/Granted	181 patents
Total Lab Space (NYC)	Over 3.1 million square feet
NIH Funding Rank (National)	#2 in the U.S. ($3.6 Billion)
Publicly Traded R&D Spend Rank	#2 in the Nation

These statistics suggest that the tiered credit structure—specifically the 20% rate for the smallest firms—is effectively supporting the “top of the funnel” for the life sciences pipeline. By nurturing these small teams, the state is building a foundation for larger companies that will eventually scale into the 15% bracket and beyond.

Comparative Analysis: Life Sciences Credit vs. Excelsior Jobs Program

For a small life sciences company, the Section 43 credit is often the most lucrative option, but it is not the only one. Understanding the interplay between different state incentives is essential for comprehensive tax planning.

The Excelsior Jobs Program R&D Credit

The Excelsior Jobs Program is a more general economic development tool that includes an R&D tax credit component.

• The Rate: The Excelsior R&D credit is 6% of the qualified research expenditures conducted in New York. For “green” projects, this rate increases to 8%.
• The Eligibility: Unlike the Life Sciences credit, which is focused on the nature of the research, the Excelsior program is focused on growth commitments. Scientific research and development firms must generally commit to creating at least 5 net new jobs to participate.
• The Difference: For a startup with fewer than 10 employees, the 20% Life Sciences credit is vastly superior to the 6% Excelsior credit. Furthermore, the Life Sciences credit does not strictly require the creation of “net new jobs” beyond meeting the “new business” test and maintaining the research activities.

Prohibition of “Double Dipping”

The state strictly prohibits taxpayers from using the same expenditures to claim multiple credits. If a company uses $1 million in wages to claim the 20% Life Sciences R&D credit, it cannot use those same wages to claim the Excelsior Jobs Program tax credit or the Investment Tax Credit (ITC). However, firms that are ineligible for the Life Sciences program (e.g., they have already exhausted their three-year window) are encouraged to apply for the Excelsior program to continue receiving support at the lower 6% rate.

Advanced Regulatory Issues: Combined Filers and Pass-Throughs

The application of the “Fewer than 10” rate becomes more complex when the qualified life sciences company is part of a larger corporate structure or operates as a pass-through entity.

Combined Group Limitations

For corporations that file a combined New York return (Form CT-3-A), the $500,000 annual cap is applied at the group level. Even if a combined group contains three separate qualified life sciences startups, the total credit for the entire group cannot exceed $500,000. Furthermore, the headcount for the 15% vs. 20% rate is typically assessed based on the specific entity that received the ESD certification, although the Tax Department may look at affiliated employees if they are part of a centralized payroll system.

Pass-Through Entity Dynamics (S-Corps and Partnerships)

When a partnership or an S-corporation earns the Life Sciences R&D Tax Credit, the credit is calculated at the entity level but is claimed by the partners or shareholders on their individual tax returns.

• Entity Level Cap: The $500,000 annual limit is applied at the entity level. If a partnership has two equal partners, they each receive $250,000 in credit, but the total cannot exceed $500,000.
• S-Corporation Pass-Through: A New York S-corporation calculates the credit using Form CT-648 but does not use the credit against its own tax liability (except for the fixed dollar minimum tax). Instead, it provides the credit information and the ESD certificate number to its shareholders, who claim it on their Form IT-648.
• LLC Treatment: Most LLCs are treated as partnerships for tax purposes. They follow the same rules as partnerships, filing Form IT-648 with their partnership return (Form IT-204) to show the total credit and then passing the credit through to their members.

This pass-through structure is particularly important for startups that are often structured as LLCs or S-corporations in their early years to allow founders to use business losses to offset other income. The refundability of the credit ensures that even if the individual partners have no other tax liability, they can still receive their portion of the credit as a cash refund.

Audit Readiness and Documentation Standards

Given the high value of the 20% credit rate and its refundable nature, the New York State Department of Taxation and Finance frequently audits these claims. Taxpayers must be prepared to defend their headcount, their “new business” status, and the qualification of their research expenditures.

Contemporaneous Records Requirement

The Department requires “contemporaneous” documentation, meaning the records must be created at the time the research is performed. A company cannot wait until an audit occurs to reconstruct its research logs or payroll records.

Critical documents include:

• Time Tracking: Detailed logs showing the percentage of time each employee spent on “qualified research services” vs. administrative or operational tasks.
• Project Descriptions: Documentation of the technical challenges being addressed, the hypothesis tested, and the scientific process followed (the “Four-Part Test” often used in federal R&D audits).
• Payroll Records: Documentation of full-time status as of December 31st and the verification of “general executive officer” roles through board minutes or bylaws.
• Supply Invoices: Receipts for materials that clearly show the items were purchased for lab use and that New York sales tax was paid or the items were otherwise sourced within the state.

The Three-Year Retention Rule

While the general statute of limitations for tax returns is three years, the specific complexity of the Life Sciences credit—and its three-year consecutive limit—means that the state may look at prior years’ certifications to determine current eligibility. Taxpayers are advised to maintain all ESD applications, certificates, and supporting QRE documentation for at least three to four years after the final year of the credit claim.

Final Thoughts

The “Fewer than 10” rate is a sophisticated and highly effective instrument of New York State tax policy. By providing a 20% refundable credit to the smallest teams in the life sciences sector, the state significantly lowers the financial barrier to entry for groundbreaking research in biotech, genomics, and medical technology. This rate is not merely a number but a reflection of a comprehensive regulatory framework that includes the “snapshot” headcount rule, the strategic exclusion of executive officers, and the prioritization of in-house New York-based innovation over outsourced contract research.

For the professional life sciences community, success in capturing this 20% rate depends on meticulous administrative compliance: filing the Consolidated Funding Application early to beat the $10 million cap, maintaining rigorous contemporaneous records of in-state QREs, and ensuring that the company’s structure meets the strict “new business” criteria. As New York continues to invest in its “Lab of the Future” and the “Cell and Gene Therapy” corridors, the Life Sciences Research and Development Tax Credit will remain a cornerstone of the state’s value proposition for the next generation of scientific entrepreneurs. Companies that master these regulations can effectively secure up to $1.5 million in non-dilutive capital over three years, providing a vital bridge from the laboratory bench to the commercial market.